ArticleFrontiers in physiology2025
Efficacy of erythrocyte apheresis in the management of severe high-altitude deacclimatization syndrome: a retrospective cohort study.
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-altitude deacclimatization syndrome (HADAS, commonly known as Oxygen toxicity) manifests through multi-organ system dysfunction and significantly deteriorates the quality of life. Unfortunately, there are no effective methods for serious HADAS (SHADAS) patients. To address this urgent public health challenge, we explored the therapeutic potential of erythrocyte apheresis (EA)-a technique previously used in HAPC treatment, and evaluated its efficacy in SHADAS patients. Methods: This retrospective cohort study analyzed clinical data of 71 SHADAS patients undergoing EA between October 2016 and September 2024 in our hematology department. Complete blood count parameters were serially measured before and after EA. Data analysis was performed using GraphPad Prism 8.02 software. Results: The study cohort exhibited significant reductions in hemoglobin (HGB) levels after initial EA: HGB decreased from 224.75 ± 12.76 g/L to 172.92 ± 22.60 g/L (males, Conclusion: Although it remains challenging to prevent SHADAS in individuals transitioning to lower altitude regions, our study demonstrated that EA could rapidly reduce HGB and alleviate associated symptoms. Moreover, we have established the parameters of EA in the treatment of SHADAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.